Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour

EJNMMI Physics

Table 5 Correlation analyses of cycle 1 SUVs, cycle 1 TADs, and cumulative TADs with diameter change (%)

	r (patient-based)	p (patient-based)	Durbin–Watson (patient-based)	r (lesion-based)	p (lesion-based)	Durbin–Watson (lesion-based)
Cycle 1 SUV_max	0.313	0.178	1.483	0.198	0.147	1.866
Cycle 1 SUV_peak	0.316	0.175	1.486	0.206	0.131	1.869
Cycle 1 SUV₄₁	0.313	0.178	1.476	0.201	0.141	1.867
Cycle 1 TAD_max (Gy)	0.327	0.160	1.527	0.209	0.126	1.86
Cycle 1 TAD_peak (Gy)	0.332	0.153	1.532	0.217	0.112	1.863
Cycle 1 TAD₄₁ (Gy)	0.326	0.161	1.519	0.21	0.123	1.861
Cumulative TAD_max (Gy)	0.428	0.060	1.668	0.301	0.025*	1.866
Cumulative TAD_peak (Gy)	0.419	0.066	1.658	0.299	0.026*	1.873
Cumulative TAD₄₁ (Gy)	0.424	0.063	1.653	0.299	0.027*	1.869

SUV: standardised uptake value, TAD: tumour-absorbed dose
Cumulative TAD: sum of the tumour-absorbed doses from all PRRT cycles
A subgroup analysis without the outlier is presented in Additional file 1: Table S4
*p < 0.05